

REMARKS

Claim 3 is canceled without prejudice.

Claims 1 and 2 are currently amended.

Claims 4 and 5 are added.

Support for the amendments to page 2, line 9; page 4, lines 11-12; Claim 1 at page 17, line 8; Claim 2 at page 18, line 2; new Claims 4 and 5; and insertion of two paragraphs at page 4, line 13 is found at page 8, lines 23-32 of the specification. Reaction of 5-bromopyridine derivative (II) with a metallizing agent listed at page 8, lines 27-32 leads to an organometallic compound (III) as shown in the amended claims, amended specification, and the two new paragraphs at page 4, line 13 of the specification.

Amendments to page 2, line 6; page 4, line 16; page 5, line 8; page 5, line 21; page 6, line 17; and Claim 1, line 9 correct minor obvious errors. "Alkoxy" is replaced with "alkoxy."

Upon entry of the amendment, Claims 1, 2, 4, and 5 will be active.

No new matter is believed to have been added. An action on the merits and allowance of the claims is requested.


Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon

Customer Number

22850

Tel: (703) 413-3000
Fax: (703) 413 -2220
(OSMMN 06/04)



Stephen G. Baxter
Attorney of Record
Registration No. 32,884